Journal of Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Toma, M. B.
Right arrow Articles by Medina, P. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Pharmacy Practice, Vol. 21, No. 1, 4-16 (2008)
DOI: 10.1177/0897190008315058
© 2008 SAGE Publications

Update on Targeted Therapy—Focus on Monoclonal Antibodies

Meredith B. Toma, PharmD

Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma

Patrick J. Medina, PharmD, BCOP

Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma, patrick-medina{at}ouhsc.edu

Monoclonal antibodies represent a diverse class of therapeutic agents frequently used in the treatment of various malignancies. Monoclonal antibodies have a common structure with varying amounts of human and nonhuman components. These agents have been developed to identify and to interact with specific cellular targets or signaling pathways, leading to cell death by various mechanisms. Adverse effects associated with monoclonal antibodies are related to their structure (human vs nonhuman content) and to their cellular targets. Pharmacists should be familiar with this class of therapeutic agents to provide effective management and to monitor patients receiving monoclonal antibody therapy.

Key Words: Monoclonal antibodies • antibody-dependent cellular cytotoxicity (ADCC) • cellular-dependent cytotoxicity (CDC) • human epidermal growth factor receptor (HER) • epidermal growth factor receptor (EGFR)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?